Zai licenses UCB's preclinical autoimmune compound

UCB Group (Euronext:UCB) granted Zai Laboratory Ltd. (Shanghai, China) an exclusive, worldwide license to develop and commercialize a preclinical mAb in all indications, including autoimmune diseases such as graft-versus-host disease (GvHD) and inflammatory bowel disease (IBD). The candidate is slated to enter Phase I testing in 2016.

UCB will receive an undisclosed upfront payment and is eligible for milestones and tiered royalties. Neither UCB nor Zai responded to inquiries. ...